GlassScriptPhysician profile
Upinder Rohewal
NPI 1407051675
$1,719.09
in general payments reported to CMS, 2019-2025
18 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $232 · 2021: $261 · 2022: $328 · 2023: $229 · 2024: $225 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $445.38 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $293.48 | 2019-2025 | Zerbaxa, Verquvo |
| Ucb, INC. | $160.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $147.91 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.77 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $135.97 | 2020-2024 | Andexxa |
| E.R. Squibb & Sons, L.L.C. | $87.68 | 2019-2023 | Eliquis |
| Pfizer INC. | $81.96 | 2019-2025 | |
| Novo Nordisk INC | $42.47 | 2025 | Rybelsus, Ozempic |
| Nabriva Therapeutics, Plc | $36.52 | 2020 | |
| Smith+Nephew, INC. | $28.55 | 2020 | |
| Boston Scientific Corporation | $24.01 | 2025 | Watchman Flx |
| Astellas Pharma US INC | $22.92 | 2024 | Cresemba |
| Actelion Pharmaceuticals US, INC. | $21.79 | 2024 | Opsumit |
| Gilead Sciences, INC. | $13.81 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $13.17 | 2023 | |
| Xeris Pharmaceuticals, INC. | $12.13 | 2022 | |
| Paratek Pharmaceuticals, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Upinder Rohewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.